DE60110043D1 - Methode zur synthetisierung von leflunomid - Google Patents

Methode zur synthetisierung von leflunomid

Info

Publication number
DE60110043D1
DE60110043D1 DE60110043T DE60110043T DE60110043D1 DE 60110043 D1 DE60110043 D1 DE 60110043D1 DE 60110043 T DE60110043 T DE 60110043T DE 60110043 T DE60110043 T DE 60110043T DE 60110043 D1 DE60110043 D1 DE 60110043D1
Authority
DE
Germany
Prior art keywords
leflunomide
trifluoromethylphenyl
isoxazole
carboxamide
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60110043T
Other languages
English (en)
Other versions
DE60110043T2 (de
Inventor
Ilya Avrutov
Neomi Gershon
Anita Liberman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of DE60110043D1 publication Critical patent/DE60110043D1/de
Application granted granted Critical
Publication of DE60110043T2 publication Critical patent/DE60110043T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60110043T 2000-02-15 2001-02-08 Methode zur synthetisierung von leflunomid Expired - Fee Related DE60110043T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18263500P 2000-02-15 2000-02-15
US182635P 2000-02-15
PCT/US2001/004095 WO2001060363A1 (en) 2000-02-15 2001-02-08 A method for synthesizing leflunomide

Publications (2)

Publication Number Publication Date
DE60110043D1 true DE60110043D1 (de) 2005-05-19
DE60110043T2 DE60110043T2 (de) 2006-03-02

Family

ID=22669359

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60110043T Expired - Fee Related DE60110043T2 (de) 2000-02-15 2001-02-08 Methode zur synthetisierung von leflunomid

Country Status (18)

Country Link
US (2) US6723855B2 (de)
EP (1) EP1257270B1 (de)
JP (1) JP2004500380A (de)
KR (1) KR20020072312A (de)
AT (1) ATE292966T1 (de)
AU (1) AU2001234943A1 (de)
CA (1) CA2400290A1 (de)
CZ (1) CZ20023024A3 (de)
DE (1) DE60110043T2 (de)
ES (1) ES2237553T3 (de)
HR (1) HRP20020671A2 (de)
HU (1) HUP0301865A3 (de)
IL (1) IL151196A0 (de)
PL (1) PL366088A1 (de)
SK (1) SK12992002A3 (de)
WO (1) WO2001060363A1 (de)
YU (1) YU61602A (de)
ZA (1) ZA200206494B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT987256E (pt) * 1997-08-08 2002-03-28 Aventis Pharma Gmbh Forma cristalina da n-(4-trifluorometilfenil)-5-metil-isoxazol-4-carboxamida
IL149792A0 (en) * 1999-12-16 2002-11-10 Teva Pharma Novel processes for making and a new crystalline form of leflunomide
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US20030139606A1 (en) * 2001-11-09 2003-07-24 Ray Anup Kumar Process for preparing 5-methylisoxazole-4-carboxylic- (4'-trifluoromethyl)-anilide
MXPA05012739A (es) * 2003-05-27 2006-05-17 Robert Per Hagerkvist Uso de inhibidor de quinasa de tirosina para tratar diabetes.
WO2005041940A1 (en) * 2003-10-30 2005-05-12 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
DE102005017592A1 (de) * 2005-04-16 2006-10-19 Lindner, Jürgen, Dr. med. Darreichungsformen und Kombinationspräparate von Pyrimidinbiosyntheseinhibitoren zur Erzielung zusätzlicher Wirkungen auf das Immunsystem
WO2007086076A2 (en) * 2006-01-24 2007-08-02 Unichem Laboratories Limited An improved process for preparation of leflunomide
CN101817797B (zh) * 2009-02-26 2013-04-10 江苏亚邦爱普森药业有限公司 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法
RU2012115459A (ru) 2009-09-18 2013-10-27 Санофи Таблетируюмый препарат (4'-трифторметилфенил)амида (z)-2-циано-3-гидрокси-бут-2-еноевой кислоты с улучшенной устойчивостью
CN102002009B (zh) * 2010-10-18 2012-11-07 齐鲁制药有限公司 一种5-甲基异恶唑-4-甲酰氯的制备方法
BR112017027175B1 (pt) 2015-06-17 2022-02-08 Biocon Limited Processo para a preparação de teriflunomida
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (de) 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
GB8619432D0 (en) 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
US5494911A (en) * 1990-05-18 1996-02-27 Hoechst Aktiengesellschaft Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
ES2124800T3 (es) 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
PT987256E (pt) * 1997-08-08 2002-03-28 Aventis Pharma Gmbh Forma cristalina da n-(4-trifluorometilfenil)-5-metil-isoxazol-4-carboxamida
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
IL149792A0 (en) * 1999-12-16 2002-11-10 Teva Pharma Novel processes for making and a new crystalline form of leflunomide

Also Published As

Publication number Publication date
EP1257270B1 (de) 2005-04-13
HUP0301865A3 (en) 2005-12-28
HRP20020671A2 (en) 2004-12-31
CA2400290A1 (en) 2001-08-23
CZ20023024A3 (cs) 2003-05-14
ES2237553T3 (es) 2005-08-01
US6723855B2 (en) 2004-04-20
AU2001234943A1 (en) 2001-08-27
JP2004500380A (ja) 2004-01-08
HUP0301865A2 (hu) 2003-09-29
US20040127532A1 (en) 2004-07-01
SK12992002A3 (sk) 2003-05-02
EP1257270A4 (de) 2003-05-07
DE60110043T2 (de) 2006-03-02
PL366088A1 (en) 2005-01-24
IL151196A0 (en) 2003-04-10
ATE292966T1 (de) 2005-04-15
YU61602A (sh) 2006-01-16
US20020022646A1 (en) 2002-02-21
WO2001060363A1 (en) 2001-08-23
EP1257270A1 (de) 2002-11-20
KR20020072312A (ko) 2002-09-14
ZA200206494B (en) 2003-08-20

Similar Documents

Publication Publication Date Title
DE60110043D1 (de) Methode zur synthetisierung von leflunomid
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
EA201000245A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
DE60219793D1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
TW200500083A (en) Formulation of human antibodies for treating tnf-α associated disorders
HUP0301802A2 (hu) Eljárás carvedilol elżállítására, kristályos carvedilol, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
ATE387197T1 (de) Cyanoalkylamino-derivate als protease-hemmer
NO20006645D0 (no) Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme
NO20061791L (no) Polymorf form av 3-fenylsulfonyl-8-piperazin-1-yl-kinolin
HUP0204010A2 (hu) Új szertralin-hidroklorid polimorfok, eljárás az előállításukra, az új polimorfokat tartalmazó gyógyszerkészítmények és alkalmazásuk
SG149045A1 (en) Novel fused pyrrolocarbazoles
MY149041A (en) Novel fused pyrrolocarbazoles
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0204069A2 (hu) Új eljárás leflunomid előállítására és a leflunomid új kristályformája és ezt tartalmazó gyógyszerkészítmény
SE0200844D0 (sv) Chemical compounds
TR200503401T1 (tr) Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları
DE69824839D1 (de) Verfahren zur herstellung von 2-aryl-3-aryl-5-halogen-pyridinen, verwendbar als cox-2 inhibitoren
ATE111455T1 (de) 3-substituierte 1,2,3,4-oxatriazol-5- iminderivate, verfahren zur herstellung sowie diese enthaltende arzneimittel.
DE60308066D1 (de) Verfahren zur herstellung von hyperpolarisiertem 129xe
ATE503476T1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
MEP38708A (en) Use of hcg and lh in controlled ovarian hyperstimulation
ATE496038T1 (de) Verfahren zur herstellung von quetiapin
ATE212019T1 (de) Verfahren zur herstellung von phenylheterocyclen die als cox-2 inhibitoren verwendet werden können

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee